Investors put $400M into biotech licensing obesity drugs from China | BioPharma Dive

Retrieved on: 2024-05-16 21:34:53

Tags for this article:

Click the tags to see associated articles and topics

Investors put $400M into biotech licensing obesity drugs from China | BioPharma Dive. View article details on hiswai:

Excerpt

Bain Capital, RTW and Atlas Venture backed the biotech, currently dubbed Hercules CM NewCo. It has a pipeline of incretin drugs licensed from ...

Article found on: www.biopharmadive.com